tbuckley/cabot-search huggingface dataset:
Abstract 2951: A genome-wide association study identifies five novel genetic markers for trastuzumab-induced cardiotoxicity
Authors: Chihiro Udagawa, Mari Hara, Arata Shimo, Yasuyuki Kojima, Reiko Yoshie, Hisamitsu Zaha, Norie Abe, Tokiwa Motonari, Mikiko Unesoko, Kenji Tamura, Tatsunori Shimoi, Masayuki Yoshida, Teruhiko Yoshida, Hiroshi Okamura, Taisei Mushiroda, Koichiro Tsugawa, Hitoshi Zembutsu
Journal: Cancer Research (2019)

Abstract Purpose: Trastuzumab has been administered to HER2-positive breast or gastric cancer patients as an effective treatment, however, the cardiotoxicity is identified as one of the life-threatening side effects. To identify a novel genetic marker(s) determining the risk of trastuzumab-induced cardiotoxicity, we performed a genome-wide association study (GWAS). Experimental Design: We carried out a GWAS using 11 cases (with trastuzumab-induced cardiotoxicity) and 257 controls (showing no sign of trastuzumab-induced cardiotoxicity). Top 100 single nucleotide polymorphisms (SNPs) which revealed smallest P value in GWAS (P = 1.61 x 10-7 -1.97 x 10-4) were further examined using replication samples consisted of 14 cases and 199 controls. Results: The combined analysis of the GWAS and replication study indicated possible association of five loci with trastuzumab-induced cardiotoxicity (chromosome 13q14.3, 4q25, 15q26.3, 17q25.3 and another 15q26.3, Pcombined = 6.00 x 10-6, 8.60 x 10-5, 1.01 x 10-4, 1.07 x 10-4, 1.60 x 10-4, respectively). Furthermore, we developed a risk prediction model for trastuzumab-induced cardiotoxicity, using five SNPs which revealed smallest P value at each locus. The incidence of trastuzumab-induced cardiotoxicity in patients with risk score ≥5 was 42.5% (P =8.69 x 10-15) . This scoring system using five candidate loci could be used to predict the risk of the adverse event before administration of trastuzumab. Conclusion: We identified five novel loci, which could be associated with trastuzumab-induced cardiotoxicity. These findings provide new insights into personalized trastuzumab therapy for patients with HER2-positive cancer. Citation Format: Chihiro Udagawa, Mari Hara, Arata Shimo, Yasuyuki Kojima, Reiko Yoshie, Hisamitsu Zaha, Norie Abe, Tokiwa Motonari, Mikiko Unesoko, Kenji Tamura, Tatsunori Shimoi, Masayuki Yoshida, Teruhiko Yoshida, Hiroshi Okamura, Taisei Mushiroda, Koichiro Tsugawa, Hitoshi Zembutsu. A genome-wide association study identifies five novel genetic markers for trastuzumab-induced cardiotoxicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2951.
United States Hospital Ships
Authors: Richard R. Hooper
Journal: JAMA (1993)

JUST after the turn of the century, the United States sent a large fleet of battleships around the world to signal its emergence as a global power. Known as the "Great White Fleet," it became a visible symbol of the strength of our military forces. This was gunboat diplomacy at its height, using naval forces to secure a political advantage.<sup>1</sup>As we move into the 21st century, we should consider using a "white fleet" again, but this time it should consist of the two hospital ships, the United States Naval Ship (USNS)<i>Mercy</i>and the USNS<i>Comfort</i>. These two white ships, emblazoned with Red Cross symbols, carry a different message to the rest of the world— that the United States is a nation of caring people, concerned about the international community and willing to help those in need. While the primary mission of the hospital ships is to provide
Patient
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CHARAKA-SAMHITA.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LACTATIONAL INSANITY.
Authors: GEORGE H. ROHÉ
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P126: Effects of Carvedilol on Mortality and Inflammatory Responses to Hemorrhagic Cardiac Arrest in Rats
Authors: Takumi Taniguchi, Hideo Inaba
Journal: Circulation (2008)

Recent studies showed that beta-blocker is often used in hypertensive and/or cardiac failure patients because of its drug efficacy. Moreover, several papers reported that beta-blocker has the beneficial effects in patients with cardiogenic shock. However, there are few studies about the effects of beta-blocker during hemorrhagic shock and hemorrhagic cardiac arrest. To evaluate the effects of beta-blocker in an animal model of hemorrhagic cardiac arrest. Carvedilol was used as the beta-blocker agents. Twenty-four male Sprague Dawley rats were used. Animals were randomly assigned to one of two groups (n = 12 per group): control group, no medication; treatment group, oral administration of carvedilol (10 mg/kg/day) for 5 days. After then, all animals were anesthetized with pentobarbital ip. Hemorrhagic cardiac arrest was induced with removing of blood. After 8 minutes of cardiac arrest, the all removing blood was administered. There were no other therapies before, during or after cardiac arrest. Hemodynamics and arterial blood gases were recorded, and mortality were calculated for the 5-hr observation period and plasma cytokine (TNF-alpha and Interleukin-6) concentrations were measured at 5-hr after cardiac arrest. The mortality rates at 5hrs after cardiac arrest were 8% and 50% for control and treatment groups, respectively. The increases of base deficit and lactate concentrations were less for the control group than the treatment group. Moreover, the increases of TNF-alpha and IL-6 concentrations were less for the control group than the treatment group. The present study showed that oral administration of carvedilol had the disadvantage effects on mortality and inflammatory effects to hemorrhagic cardiac arrest in rats. These finding suggest that beta-blocker may worsen the recovery of hemorrhagic shock.
RADIOTHERAPEUTIC OBSERVATIONS.
Authors: JOSEPH ZEISLER
Journal: JAMA (1903)

The employment of the mysterious<i>x</i>-rays for the treatment of various skin diseases has ceased to be the monopoly of a few privileged promoters and is gradually becoming almost indispensable in the work of the up-to-date dermatologist. Much has been learned in this new field of practical medicine. More remains to be accomplished before the new agent can be handled with scientific accuracy. At the present moment there is still a deplorable diversity of opinion concerning some vital points in the theory and practice of radiotherapy. The controversy as to the real active principle emanating from the Crookes' tube is apparently still unsettled. Freund and Kienboeck may be mentioned as important representatives of the two opposing factions. The former, after persistently attributing the bulk of the<i>x</i>-ray effects to peculiar electric discharges or waves from the tube, seems of late to somewhat recede from his position. Kienboeck, who regards the
A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).
Authors: Hossein Borghaei, Thomas James Lynch, Naiyer A. Rizvi, Laura Quan Man Chow, Robert Reilly, Lucio Crinò, Marc E. Buyse, Rana Ezzeddine, Brian Joseph Lestini, Julie R. Brahmer
Journal: Journal of Clinical Oncology (2013)

TPS8122 Background: NSCLC is the leading cause of cancer death worldwide, exceeding breast, colon and prostate cancer combined. Most patients (pts) are diagnosed with advanced/recurrent disease. NSCLC therapies have incrementally improved overall survival (OS), but benefit has reached a plateau (median OS for late stage pts is just 1 yr). Squamous cell carcinoma (SCC) represents one quarter of NSCLC cases and has limited treatment options. Pemetrexed and bevacizumab are not approved in SCC, and molecularly targeted therapies have limited application. Single-agent chemotherapy is standard of care following progression with platinum-based doublet chemotherapy (Pt-doublet), resulting in median OS of approximately 7 months. Immune checkpoint blockade in NSCLC may promote tumor regression by reversing tumor-induced immunosuppression and restoring the antitumor immune response. Programmed death-1 (PD-1), an immune checkpoint receptor that negatively regulates T-cell activation, is upregulated in tumor infiltrating lymphocytes; expression of its ligand PD-L1 has been associated with poor prognosis in NSCLC. Nivolumab, a PD-1 receptor blocking antibody, showed encouraging antitumor activity in SCC pts in a phase 1 study, with objective responses (ORs) in 4 pts (27%) and stable disease ≥24 weeks in 1 pt (7%) (3 mg/kg; n=15) (Gettinger S et al; ESMO 2012 [Abstr 1237PD]). We describe an ongoing open-label phase 3 study to compare the clinical benefit of nivolumab vs docetaxel in advanced/metastatic SCC pts following failure of Pt-doublet. Methods: A total of 264 pts will be randomized 1:1 to nivolumab monotherapy 3 mg/kg IV every 2 weeks or docetaxel 75 mg/m 2 every 3 weeks until disease progression or unacceptable toxicity. Pts will be stratified by prior paclitaxel use and geographic region. Tumor response will be assessed using modified RECIST 1.1. The co-primary objectives are OR rate and OS. Secondary objectives include progression free survival, clinical benefit in PD ligand 1 (PD-L1+) and PD-L1– subgroups (archived tissue required for entry), durability of and time to OR, and pt proportion with symptom improvement. Clinical trial information: NCT01642004.
The physician's role in preventing alcohol-related injuries
Authors: J. R. Waller
Journal: JAMA (1988)

Identifying potential areas for successful patient counseling to prevent or reduce high-risk behavior is one of the ongoing goals of the medical profession. Three steps are required. First, a predictive relationship between a given behavior and a harmful outcome must be documented. Second, there must be an easy way to communicate this information to the patient within the context and constraints of the typical medical practice. Third, there must be evidence that such communication can reduce risk effectively. The article by Anda et al in this issue ofTHE Journal<sup>1</sup>clearly fulfills the first of these requirements. Prospective analysis of deaths over a nine-year period among more than 13 000 adults revealed that for both men and women, self-reported heavy consumption of alcohol is predictive of a greater likelihood of subsequent death from injury. Persons who initially reported consuming five or more drinks per occasion as their usual quantity
Health care financing and delivery in the decade ahead
Authors: W. J. McNerney
Journal: JAMA (1972)

One hundred eighty-six years ago, Robert Burns pleaded that we might be given the power to see ourselves as others see us. If that plea proves anything, it is that 18th century Scotland was not blessed with the newspapers and television news broadcasts that we in the United States enjoy today. Through them, we have indeed been given the power to see ourselves through the eyes of others. All we have to do is read or listen. For example: Rochester, NY, November 1971.— Surveys in the area were reported to show that because of a lack of areawide planning, 30% of all hospital and nursing home patients should have been cared for elsewhere. Chicago, February 1972.—Dr. Huntley, of the Department of Health, Education and Welfare, said 60,000 lives could be saved annually if present knowledge about emergency care were put into effect. He added that only eight to ten communities
Symptomatic and Regional Therapeutics.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Cover
Authors: Harriet O. Kelley
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Common Patterns of Water and Electrolyte Change in Injury, Surgery and Disease
Authors: Francis D. Moore
Journal: New England Journal of Medicine (1958)

THE years since World War II have witnessed an intensive exploration of the metabolic changes of trauma, surgery, acute disease and chronic wasting illness. Metabolism has been measured by metabolic balance methods, body composition and membrane transfer by the study of isotope exchange, and endocrine changes by hormone assay. Although the picture is far from complete, and interpretations have been halting, stumbling or downright erroneous, a mass of new data has emerged that is of assistance in the daily bedside care of the sick.Some of the most useful data bear on the recognizable patterns of water-electrolyte change seen in . . .
Anorectal Operative Procedures with Special Reference to Avoidance of Pain
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Premonitions
Authors: Joseph E. Hardison
Journal: JAMA (1984)

Mr Davis was a nice man. He had chronic lymphocytic leukemia and angina pectoris. Both diseases were well controlled. His angina occurred infrequently and responded promptly to sublingual nitroglycerin. His chronic leukemia required no treatment. I was satisfied with how Mr Davis was doing, but he wasn't. He was frightened of his diseases. Because of his anxiety he came to see me often. He came with his wife, who understood him. She knew he was scared. She loved him and was supportive, but not overly so. They lived in the country and had a good garden. Mr Davis was proud of his okra, corn, tomatoes, string beans, and black-eyed peas. In the summertime they enjoyed bringing me a "mess" of fresh vegetables. I would examine him, check his blood count, and try my best to reassure him. He would thank me, confirm his next appointment, and leave preoccupied with his
The prognostic role of PD L1 expression according to MSI status in stage III colon cancer after curative resection.
Authors: Sang-Hee Cho, Ka-Rham Kim, Hyung-jung Shim, Woo Kyun Bae, Jun Eul Hwang, Ik-Joo Chung
Journal: Journal of Clinical Oncology (2016)

e15128 Background: Tumors expressing programmed death ligand 1 (PD-L1) can render immune inactivated via triggering of PD-1 receptor on T cells with various pathways. In the present study, we evaluated the prognostic role of PD-L1 expression associated with microsatellite status in surgically resected stage III colon cancer patients. Methods: PD-L1 expression was performed by immunohistochemistry from 182 stage III colon cancer patients after curative resection at a single institution. Percentages of PD-L1 positive tumor cells and staining intensity were evaluated and tumors with weak or moderate expression were collectively classified as ‘low’ PD-L1 positive. Clinical and histopathologic parameters including of MSI status were analyzed. Results: Strong PD-L1 expression was observed in 29% of all patients. Perineural invasion and lymphocyte response were more frequently shown in strong expression of PD-L1 patients. Among these patients, MSI was shown in 23 patients (12%). Although there was no significant difference between microsatellite status and PD-L1 expression, strong PD-L1 tended to better overall survival in microsatellite stable (MSS) colon cancer (P = 0.056). In contrast, strong PD-L1 expression significantly correlated with significantly worse prognosis in disease free survival (P = 0.001) and overall survival (P < 0.001) than weak PD-L1 expression in microsatellite instability (MSI) patients regardless of adjuvant chemotherapy. In MSI patients, the strong IDO expression was tended to be more frequently shown in strong PD-L1 expression patients (36.4%) than weak PD-L1 expression patients (14.3%) without significance. Conclusions: The expression of PD-L1 is differently affected on the survival according to the status of microsatellite. There is no significant relationship between the expression of PD-L1 and prognosis in MSS stage III colon cancer patients. However, in MSI colon cancer which has been well known as a highly immunogenic property, strong PD-L1 expression is significantly associated with poor prognosis on disease free survival and overall survival in curative resected stage III colon cancer patients.